Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 23 recruiting now early-phase tilt

Colorectal Neoplasms: early-phase trial registry

23 of 55 indexed Colorectal Neoplasms trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #254 of 28,707 conditions by registered trial count.

55 US clinical trials · 23 currently recruiting · #254 of 28,707 conditions by registered trial count

Colorectal Neoplasms: 55 US clinical trials tracked, 23 recruiting.

Colorectal Neoplasms is the subject of 55 registered US clinical trials on ClinicalTrials.gov, 23 of them currently open to new participants. 9 are in Phase 3-4 (later-stage) and 31 in Phase 1-2 (earlier-stage). The most active sponsor is National Cancer Institute (NCI), running 7 of these trials.

Enrollment posture brief

Registry condition colorectal-neoplasms

OPEN 23 | RECR 42% | LATE 9 | EARLY 31 | RANK #254 | SPON 7

Nearest open-share peer: Stress (42% recruiting · 153 trials)

Colorectal Neoplasms (this)42%Down Syndrome38.2%Menopause32.7%Constipation27.3%Brain and Central Nervous Sy1.8%
Open-enrollment share among volume-matched conditions near Colorectal Neoplasms

Colorectal Neoplasms lists 23 open slots (42% of 55 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Colorectal Neoplasms on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Colorectal Neoplasms is recruiting above its size-band peers.

    23 of 55 indexed trials (41.8%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. Sponsorship of Colorectal Neoplasms trials is spread across many organizations.

    National Cancer Institute (NCI) accounts for 7 of 55 trials (12.7%). 30 distinct sponsors appear on at least one study for this condition label.

  3. Typical Colorectal Neoplasms enrolment sits around 268 participants.

    Median target enrolment is 268 among the 55 trials that report a genuine target (sentinel values excluded). 16 of those (29.1%) plan for fewer than 100 participants.

  4. Colorectal Neoplasms research is mostly interventional.

    48 interventional and 7 observational studies make up this index (87.3% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 123Phase 28Phase 38Phase 41

Phase Distribution

PhaseTrial count
Phase 1 23
Phase 2 8
Phase 3 8
Phase 4 1

Named interventions

Most-linked intervention names on Colorectal Neoplasms records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

bevacizumab Drug
3 trials
5-fluorouracil Drug
3 trials
Oxaliplatin Drug
3 trials
pembrolizumab Drug
3 trials
E7386 Drug
2 trials
Leucovorin calcium/Levoleucovorin Drug
2 trials
Fluorouracil Combination
2 trials
Cetuximab Combination
2 trials

US sites by state

Facility locations filed on Colorectal Neoplasms trials. A trial with sites in several states counts in each.

California 30 trials
Florida 18 trials
Texas 16 trials
New York 14 trials
Michigan 12 trials
Maryland 12 trials
Massachusetts 12 trials
Colorado 12 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Colorectal Neoplasms page

55 registered trials, 23 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Colorectal Neoplasms condition card totals 55 registered trials; most-linked intervention bevacizumab; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.